Loomis, Sayles & Company
IOVA icon

Loomis, Sayles & Company’s Iovance Biotherapeutics IOVA Stock Holding History

Loomis, Sayles & Company’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-277
Closed -$13K – 862
2020
Q4 		$13K Buy
+277
New +$11K ﹤0.01% 679

Other funds holding IOVA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Loomis, Sayles & Company's IOVA Position: Q1 2021 in Review

Loomis, Sayles & Company sold out of Iovance Biotherapeutics (IOVA) in Q1 2021, closing a stake of 277 shares — an estimated $13K sold.

Loomis, Sayles & Company first reported a position in IOVA in Q4 2020 and held it in 1 quarter. The position peaked at $13K in Q4 2020. 251 funds tracked by Wall St. Rank hold IOVA as of Q1 2021.

  • Loomis, Sayles & Company reported no remaining Iovance Biotherapeutics position as of Q1 2021 after selling out during the quarter.
  • Loomis, Sayles & Company sold 277 Iovance Biotherapeutics shares in Q1 2021, an estimated $13K.
  • Loomis, Sayles & Company first reported a position in Iovance Biotherapeutics in Q4 2020 and held it in 1 quarter.
  • Loomis, Sayles & Company's Iovance Biotherapeutics position peaked at $13K in Q4 2020.
  • 251 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2021.

Based on Loomis, Sayles & Company's 13F filing for Q1 2021, filed 17 May 2021.